StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note released on Wednesday. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Up 2.2 %

TXMD opened at $1.83 on Wednesday. The stock’s 50 day moving average price is $1.91 and its 200-day moving average price is $2.10. TherapeuticsMD has a one year low of $1.43 and a one year high of $4.35.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Friday, May 10th. The company reported ($0.07) EPS for the quarter. The business had revenue of $0.31 million during the quarter.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC acquired a new position in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD as of its most recent SEC filing. 30.74% of the stock is owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.